Why the study?
Does an atrial antitachycardia pacemaker reduce medical costs and improve quality-of-life compared to medical therapy alone in patients with refractory supraventricular tachyarrhythmias?
Population
17 patients with refractory supraventricular tachyarrhythmias
Comparison
Atrial antitachycardia pacemaker vs Prior medical therapy
Design
Cohort
Follow-up
15.3 +/- 7.8 months for costs, 36.6 +/- 11 months for…
Authors
Loading...
Associated with lower costs and better QoL after antitachycardia pacing; hypothesis-generating and requires randomized confirmation.
Does an atrial antitachycardia pacemaker reduce medical costs and improve quality-of-life compared to medical therapy alone in patients with refractory supraventricular tachyarrhythmias?
Atrial antitachycardia pacemakers appear to be cost-competitive over time and improve quality-of-life compared to medical therapy alone in patients with refractory supraventricular tachyarrhythmias.
LI et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: